Abstract
Systemic sclerosis is a rare auto-immune disease that involves immune cells, fibroblasts and endothelial cells. Depending on the cutaneous extend, the sclerosis may be either limited or diffuse. Whatever the form, all are associated with a high risk of visceral involvement, particularly digestive, pulmonary, cardiac and renal, resulting in an increased risk of mortality. Sclerodactily and digital ulcers alter considerably the patients' quality of live. Regular visceral check-up, adequate use of calcium channel blockers, ACE inhibitors and proton pump inhibitors, and the development these past 15 years of new drugs such as prostacyclins and analogues, endothelin receptor inhibitors, improve the patients survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
